title: Oral Valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age.
authors.forename: A
authors.initials: A
authors.lastname: Hilgendorff
authors.forename: A
authors.initials: A
authors.lastname: Daiminger
authors.forename: V
authors.initials: V
authors.lastname: Dangel
authors.forename: J
authors.initials: J
authors.lastname: Kreuder
authors.forename: C
authors.initials: C
authors.lastname: Geidel
authors.forename: I
authors.initials: I
authors.lastname: Reiss
authors.forename: G
authors.initials: G
authors.lastname: Enders
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D008134:Long-Term Care; D008297:Male; D015997:Neonatal Screening; D056687:Off-Label Use; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir